Michel Héaulme

4.3k total citations · 1 hit paper
34 papers, 3.5k citations indexed

About

Michel Héaulme is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Physiology. According to data from OpenAlex, Michel Héaulme has authored 34 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Cellular and Molecular Neuroscience, 17 papers in Molecular Biology and 4 papers in Physiology. Recurrent topics in Michel Héaulme's work include Neuroscience and Neuropharmacology Research (16 papers), Receptor Mechanisms and Signaling (13 papers) and Neuropeptides and Animal Physiology (10 papers). Michel Héaulme is often cited by papers focused on Neuroscience and Neuropharmacology Research (16 papers), Receptor Mechanisms and Signaling (13 papers) and Neuropeptides and Animal Physiology (10 papers). Michel Héaulme collaborates with scholars based in France, United Kingdom and Italy. Michel Héaulme's co-authors include Philippe Soubrié, Gérard Le Fur, G. Néliat, Murielle Rinaldi‐Carmona, Christian Congy, David Shire, Francis Barth, Pascual Ferrara, Bernard Calandra and Daniel Caput and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Brain Research and FEBS Letters.

In The Last Decade

Michel Héaulme

33 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

1994 1.5k citations Murielle Rinaldi‐Carmona, Francis Barth et al. profile →

Peers

Countries citing papers authored by Michel Héaulme

Since Specialization

Citations

This map shows the geographic impact of Michel Héaulme's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Héaulme with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Héaulme more than expected).

Fields of papers citing papers by Michel Héaulme

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michel Héaulme. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Héaulme. The network helps show where Michel Héaulme may publish in the future.

Co-authorship network of co-authors of Michel Héaulme

This figure shows the co-authorship network connecting the top 25 collaborators of Michel Héaulme. A scholar is included among the top collaborators of Michel Héaulme based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michel Héaulme. Michel Héaulme is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SR146131: A New Potent, Orally Active, and Selective Nonpeptide Cholecystokinin Subtype 1 Receptor Agonist. II: In Vivo Pharmacological Characterization 1999 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown), Richard Alonso, M. Arnone, Robert Boigegrain, (unknown), Christiane Gueudet, Michel Héaulme, Peter Keane, Marco Landi, (unknown), (unknown), Martine Poncelet, (unknown), Jacques Simiand, Philippe Soubrié, Marc Pascal, J.P. Maffrand, Gérard Le Fur	25
2	Stimulation by neurotensin of (3H)5-hydroxytryptamine (5HT) release from rat frontal cortex slices 1998 ·Neuropeptides ·Michel Héaulme, Roger Leyris, Philippe Soubrié, G. Le Fur	10
3	Involvement of potentially distinct neurotensin receptors in neurotensin-induced stimulation of striatal [3H]dopamine release evoked by KC1 versus electrical depolarization 1997 ·Neuropharmacology ·Michel Héaulme, Roger Leyris, Gérard Le Fur, Philippe Soubrié	18
4	Biochemical and pharmacological characterisatioN OF SR141716A, the first potent and selective brain cannabinoid receptor antagonist 1995 ·Life Sciences ·Murielle Rinaldi‐Carmona, Francis Barth, Michel Héaulme, Richard Alonso, David Shire, Christian Congy, Philippe Soubrié, Jean-Claude Brelière, Gérard Le Fur	269
5	SR 48692 inhibits neurotensin-induced [3H]dopamine release in rat striatal slices and mesencephalic cultures 1994 ·European Journal of Pharmacology ·Aline Brouard, Michel Héaulme, Roger Leyris, Didier Pélaprat, Danielle Gully, Patrick Kitabgi, Gérard Le Fur, William Rostène	23
6	SR 142801, The first potent non-peptide antagonist of the tachykinin NK3 receptor 1994 ·Life Sciences ·Xavier Emonds‐Alt, (unknown), (unknown), Michel Héaulme, Brigitte Miloux, Martine Poncelet, Vincenzo Proietto, Didier Van Broeck, P. Vilain, G. Néliat, P. Soubrié, G. Le Fur, (unknown)	201
7	Neurotensin receptor interaction with dopaminergic systems in the guinea-pig brain shown by neurotensin receptor antagonists 1994 ·European Journal of Pharmacology ·Mounia Azzi, Danielle Gully, Michel Héaulme, Anne Bérod, Didier Pélaprat, Patrick Kitabgi, Robert Boigegrain, J.P. Maffrand, (unknown), William Rostène	25
8	SR 57227A: a potent and selective agonist at central and peripheral 5-HT3 receptors in vitro and in vivo 1993 ·European Journal of Pharmacology ·André Bachy, Michel Héaulme, A Giudice, (unknown), (unknown), J. Souilhac, L. Manara, M.B. Emerit, H. Gozlan, M. Hamon, P.E. Keane, Philippe Soubrié, (unknown)	70
9	In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist 1993 ·European Journal of Pharmacology ·Xavier Emonds‐Alt, Jean-Daniel Doutremepuich, Michel Héaulme, G. Néliat, Vincent Santucci, R. Steinberg, P. Vilain, (unknown), (unknown), Vincenzo Proietto, Didier Van Broeck, Philippe Soubrié, Gérard Le Fur, Jean-Claude Brelière	337
10	Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist 1993 ·Naunyn-Schmiedeberg s Archives of Pharmacology ·Martine Poncelet, M. Arnone, Michel Héaulme, (unknown), Christiane Gueudet, Vincent Santucci, (unknown), Peter Keane, D. Gully, G. Le Fur, (unknown)	23
11	35 mM K+-stimulated 45Ca2+ uptake in cerebellar granule cell cultures mainly results from NMDA receptor activation 1993 ·European Journal of Pharmacology Molecular Pharmacology ·Michel Didier, Michel Héaulme, (unknown), (unknown), Joël Bockaert, Jean‐Philippe Pin	19
12	Synthesis and biochemical evaluation of baclofen analogs locked in the baclofen solid-state conformation 1991 ·Journal of Medicinal Chemistry ·André Mann, (unknown), (unknown), F. Durant, G. Evrard, Michel Héaulme, (unknown), Camille G. Wermuth	42
13	Rapid, sensitive, and simple method for quantification of both neurotoxic and neurotrophic effects of NMDA on cultured cerebellar granule cells 1990 ·Journal of Neuroscience Research ·Michel Didier, Michel Héaulme, Philippe Soubrié, Joël Bockaert, Jean‐Philippe Pin	47
14	The sensitivity of γ-aminobutyric acid antagonists to thiocyanate is related to the absence of a functional anionic group in their structure 1987 ·European Journal of Pharmacology ·Camille G. Wermuth, J. P. Chambón, Michel Héaulme, Anita Melikian, Gilbert Schlewer, Roger Leyris, Kathleen Bizière	4
15	Characterization of the Binding of [³H]SR 95531, a GABA_A Antagonist, to Rat Brain Membranes 1987 ·Journal of Neurochemistry ·Michel Héaulme, Jean‐Pierre Chambon, Roger Leyris, Camille G. Wermuth, Kathleen Bizière	80
16	Evaluation of two anticonvulsant amino-pyridazine derivatives in the conflict test in rats. 1986 ·Journal of Pharmacology and Experimental Therapeutics ·A. Pério, J. P. Chambón, (unknown), Michel Héaulme, Kathleen Bizière	13
17	Biochemical characterization of the interaction of three pyridazinyl-GABA derivatives with the GABAA receptor site 1986 ·Brain Research ·Michel Héaulme, Jean‐Pierre Chambon, Roger Leyris, (unknown), Camille G. Wermuth, Kathleen Bizière	110
18	Specific binding of a phenyl-pyridazinium derivative endowed with GABAA receptor antagonist activity to rat brain 1986 ·Neuropharmacology ·Michel Héaulme, J. P. Chambón, Roger Leyris, Camille G. Wermuth, Kathleen Bizière	16
19	CM 40907: a structurally novel anticonvulsant in mice, rats and baboons. 1985 ·Journal of Pharmacology and Experimental Therapeutics ·J. P. Chambón, (unknown), (unknown), Michel Héaulme, (unknown), R. Roncucci, Kathleen Bizière	10
20	Prostaglandins of the E series inhibit release of noradrenaline in rat hypothalamus by a mechanism unrelated to classical α2 adrenergic presynaptic inhibition 1984 ·Neuropharmacology ·F. Dray, Michel Héaulme	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact